Key result
Vitamin D lowers lipids and cardiac markers in obese rats, suggesting protection against subclinical atherosclerosis.
Why the study?
The exact link between obesity, vitamin D deficiency, and cellular senescence in the pathogenesis of subclinical atherosclerosis remains under debate, along with the potential protective role of vitamin D supplementation.
Does vitamin D supplementation improve biomarkers of subclinical atherosclerosis and cellular senescence in an obese rat model?
Does vitamin D supplementation improve biomarkers of subclinical atherosclerosis and cellular senescence in an obese rat model?
Vitamin D supplementation may protect against obesity-associated subclinical atherosclerosis and endothelial dysfunction by modulating cellular senescence in a preclinical model.
May support preclinical investigation of vitamin D in obesity-related atherosclerosis; leaves open translation to human trials.
The exact link between obesity, vitamin D deficiency, and their relation to cellular senescence in the pathogenesis of subclinical atherosclerosis is still under debate. Therefore, the current study aims to verify the possible role of vitamin D deficiency and cellular senescence in the pathogenesis of obesity-related subclinical atherosclerosis. Moreover, it aims to investigate the possible protective role of vitamin D supplementation. Fifty-seven male albino rats were enrolled in the study and classified into four groups: negative (10) and positive control groups (10), an obese model group (24), and a vitamin-D-supplemented obese group (13). Aortic tissue samples and fasting blood samples were collected. The following biochemical investigations were performed: serum cholesterol, triglycerides, HDL-C, LDL-C, ALT, AST, CPK, CK-MB, and hs-cTnt. HOMA-IR was calculated. Moreover, serum SMP-30, 25 (OH)Vitamin D3, and eNOS were determined by the ELISA technique. Aortic gene expression of eNOS, SMP-30, and P53 was estimated by real-time qRT-PCR. Serum 25(OH) D3 and SMP-30 were lower in the obese group. In addition, the obese group showed higher serum lipid profile, HOMA-IR, eNOS, ALT, AST, CPK, CK-MB, and hs-cTnt than the control groups, while decreased levels were found in the vitamin-D-treated obese group. Gene expression of eNOS and SMP-30 were in accordance with their serum levels. A positive correlation was found between vitamin D level and SMP-30. In conclusion, obesity is associated with vitamin D deficiency and enhanced cellular senescence. They could play a role in the pathogenesis of obesity-associated subclinical atherosclerosis and endothelial dysfunction. Vitamin D supplements could play a protective role against such obesity-related comorbidity.
No takes yet. Share an insight, caveat, or question.
Bima et al. (2021) studied Obesity-associated subclinical atherosclerosis (n=57). Vitamin D supplementation vs. Obese model group and control groups was evaluated on Biochemical markers including serum lipid profile, HOMA-IR, eNOS, ALT, AST, CPK, CK-MB, hs-cTnt, SMP-30, and 25(OH)D3. Vitamin D supplementation in obese rats decreased serum lipid profile, HOMA-IR, and cardiac markers compared to untreated obese rats, suggesting protection against subclinical atherosclerosis.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: